Abstract: Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.
Type:
Grant
Filed:
August 13, 2021
Date of Patent:
May 23, 2023
Assignee:
Elixir Medical Corporation
Inventors:
Motasim Sirhan, Xiaoxia Zheng, Vinayak D. Bhat, John Yan
Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.
Type:
Grant
Filed:
November 22, 2022
Date of Patent:
May 16, 2023
Assignee:
HDT BIO CORP.
Inventors:
Amit Khandhar, Steven Reed, Malcolm Duthie, Jesse Erasmus, Darrick Carter, Bryan J. Berube
Abstract: The disclosure provides nanoemulsion compositions and methods of making and using thereof to deliver a bioactive agent such as a nucleic acid to a subject. The nanoemulsion composition comprises a hydrophobic core based on inorganic nanoparticles in a lipid nanoparticle that allows imaging as well as delivering nucleic acids. Methods of using these particles for treatment and vaccination are also provided.
Type:
Grant
Filed:
August 22, 2022
Date of Patent:
May 16, 2023
Assignee:
HDT BIO CORP.
Inventors:
Amit Khandhar, Steven Reed, Malcolm Duthie, Jesse Erasmus, Darrick Carter, Bryan J. Berube
Abstract: A method of selecting skin treatment regimens, ingredients and compositions that includes measuring the levels of particular small molecule metabolites on skin both before and after product application and testing for a change in small molecule metabolite levels is disclosed.
Abstract: The present invention is directed to bioresorbable polymers to be used as bone and tissue adhesives. The present invention is also directed to the synthesis of bioresorbable polymeric molecules bearing adhesive moieties and the use of such compounds in methods to glue and stabilize fractured bones and damaged tissues. The present invention is also directed to the use of such compounds as adhesive sealants for applications in wound care. The present invention is also directed to the use of such compounds as biodegradable ink for applications in tissue engineering and 3D printing. The present invention also relates to the use of such compounds as drug delivery platforms.
Type:
Grant
Filed:
April 27, 2018
Date of Patent:
May 9, 2023
Assignee:
Evonik Operations GmbH
Inventors:
Teng Xue, Gianluigi Luppi, Natalia Ruggeri Savietto, Howard K. Bowman, III, Paul Joseph Spencer, Andreas Karau, Jian-Feng Zhang, Rosario Lizio, Marshall Scott Jones
Abstract: Methods are disclosed for the reduction or elimination of bacterial biofilms on biological and non-biological surfaces, as well as methods for the treatment of wounds, skin lesions, mucous membrane lesions, and other biological surfaces infected or contaminated with bacterial biofilms using compositions comprising thermolysin.
Type:
Grant
Filed:
July 26, 2017
Date of Patent:
April 18, 2023
Assignee:
SMITH & NEPHEW, INC.
Inventors:
Lei Shi, Catherine Van Der Kar, Aleksa Jovanovic, Eric Roche
Abstract: The present invention relates to the treatment of ocular diseases in a human subject In particular, the invention relates to an intracameral administration of a sustained release biodegradable intracameral implant.
Type:
Grant
Filed:
February 16, 2022
Date of Patent:
April 11, 2023
Assignee:
OCULAR THERAPEUTIX, INC.
Inventors:
Charles D. Blizzard, Ankita Desai, Arthur Driscoll, Michael Goldstein
Abstract: A liposome composition having a lipid bilayer membrane, made of a crude or de-oiled lecithin, at least one triglyceride, a non-triglyceride active agent, and conditioned water. The liposome composition may be utilized for purposes and treatments including increased plant growth, insecticide or insect repellant, inhibiting fruit decay, forensic labeling of plants, wound treatment, and cosmetic applications.
Abstract: In some aspects, the present invention provides surgical procedures that comprise applying compositions into and/or onto tissue, including supporting tissues (e.g., ligaments, connective tissue, muscles, etc.) for pelvic organs, among other tissues. In other aspects, the present disclosure pertains to compositions that are useful for performing such procedures. In still other aspects, the present disclosure pertains to kits that are useful for performing such procedures.
Type:
Grant
Filed:
December 22, 2021
Date of Patent:
April 11, 2023
Assignee:
BOSTON SCIENTIFIC SCIMED, INC.
Inventors:
Sandra Nagale, Mark W. Boden, Andrew Dolan
Abstract: Composite nerve guides for nerve regeneration are provided, wherein the composite guide comprise a nerve graft and a nerve conduit continuing an active agent that promote axon regeneration. The devices can provide structural supports to guide nerve regeneration and locally deliver an active agent (e.g., glial cell-line derived neurotrophic factor (GDNF) and/or glial growth factor 2 (GGF2) to injured nervous system tissue upon implantation in a subject. Methods of treatment using such devices are also provided.
Type:
Grant
Filed:
November 13, 2018
Date of Patent:
April 11, 2023
Assignee:
University of Pittsburgh—of the Commonwealth System of Higher Education
Abstract: Described herein are polymeric particles configured for intravascular delivery of pharmaceutical agents, e.g., to a diseased site, and methods of forming and using same. Preparation of these polymer particles is also described.
Type:
Grant
Filed:
June 26, 2020
Date of Patent:
April 4, 2023
Assignee:
Terumo Corporation
Inventors:
Gregory M. Cruise, Xinping Wu, Gloria Hincapie, Yue Wu
Abstract: The invention relates to pharmaceutical compositions in liquid form comprising pradofloxacin in an aqueous solution and citric acid or thioglycerol as antioxidants.
Abstract: Drug-loaded microbead compositions include microbeads of a water-swellable polymer material and a complex of a carrier and a therapeutic agent chemically bonded to the carrier. The complex is embedded in the polymer material. The therapeutic agent is not chemically bonded to the water-swellable polymer material. The drug-loaded microbead composition has a water content of less than 1% by weight, based on the total weight of the drug-loaded microbead composition. The drug-loaded microbead composition may be rehydrated to form an embolization composition for use in in embolization therapy. Methods for preparing the drug-loaded microbead compositions and the embolization compositions include loading a therapeutic agent into a water-swellable polymer material to form microbeads, then removing water from the microbeads.
Abstract: An anti-caking or flow agent is provided herein. The anti-caking or flow agent may include a bamboo extract that may include silica and carbohydrate. The bamboo extract may have a loose density (g/ml) of from about 0.14 g/ml to about 0.18 g/ml or a tapped density (g/ml) of from about 0.18 g/ml to about 0.22 g/ml. The bamboo extract may also include particles of the silica and the carbohydrate, wherein the particles have a size (Dv50) of from about 35 ?m to about 55 ?m. This anti-caking or flow agent may facilitate the manufacture, packaging, or storage of dry powdered food ingredients and food products such as spices, flavorings, and powdered food mixes as well as pharmaceuticals and nutraceuticals.
Abstract: Drug-loaded microbead compositions include microbeads of a biodegradable material and vesicular agents located within or associated with the biodegradable material of the microbeads. The vesicular agents include a lipid bilayer and comprise liposomes or ethosomes. The drug-loaded microbeads include a first therapeutic agent associated with the vesicular agents, and a second therapeutic agent different from the first therapeutic agent. The vesicular agents include a lipid bilayer surrounding a vesicular core. The second therapeutic agent is contained within the microbeads or associated with the microbeads through ionic or non-covalent interaction and may or may not be associated with the vesicular agents. Drug-loaded biodegradable microbead compositions include microbeads of biodegradable material and a therapeutic agent.
Type:
Grant
Filed:
June 26, 2020
Date of Patent:
February 28, 2023
Assignee:
C.R. Bard, Inc.
Inventors:
Elena Afonina, Hiep Do, Emily Goel, Oleg Guryev, Cyal Lecy, Majid Mehrpouyan, Michael Randall, Marybeth Sharkey, Jeffrey Wang
Abstract: Provided herein are methods for treating progressive familial intrahepatic cholestasis (PFIC) with an ileal bile acid transport (IBAT) inhibitor such as odevixibat, or a pharmaceutically acceptable salt thereof. Such methods can include reducing mean pruritus score, mean serum bile acid concentration, increasing height, normalizing weight, improving sleep, and improving liver parameters.
Type:
Grant
Filed:
December 10, 2021
Date of Patent:
February 21, 2023
Assignee:
Albireo AB
Inventors:
Per-Göran Gillberg, Jan Mattsson, Pat Horn, Paresh Soni